Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,085
archived clinical trials in
Cervical Cancer

Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
University of Mississippi Medical Center
mi
from
Jackson, MS
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
University of Mississippi Medical Center
mi
from
Jackson, MS
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Centerpoint Medical Center LLC
mi
from
Independence, MO
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Centerpoint Medical Center LLC
mi
from
Independence, MO
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Truman Medical Center
mi
from
Kansas City, MO
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Truman Medical Center
mi
from
Kansas City, MO
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Saint Louis University Hospital
mi
from
Saint Louis, MO
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Saint Louis University Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Mercy Hospital Springfield
mi
from
Springfield, MO
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Mercy Hospital Springfield
mi
from
Springfield, MO
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Ozark Health Ventures LLC dba Cancer Research for The Ozarks Springfield
mi
from
Springfield, MO
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Ozark Health Ventures LLC dba Cancer Research for The Ozarks Springfield
mi
from
Springfield, MO
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Cooper Hospital University Medical Center
mi
from
Camden, NJ
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Women's Cancer Care Associates
mi
from
Albany, NY
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Women's Cancer Care Associates
mi
from
Albany, NY
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Carolinas Medical Center
mi
from
Charlotte, NC
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Carolinas Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Gynecologic Oncology Network
mi
from
Greenville, NC
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Gynecologic Oncology Network
mi
from
Greenville, NC
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
MetroHealth Med Ctr
mi
from
Cleveland, OH
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Riverside Methodist Hospital
mi
from
Columbus, OH
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Riverside Methodist Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Tulsa Cancer Institute, Pllc
mi
from
Tulsa, OK
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Tulsa Cancer Institute, Pllc
mi
from
Tulsa, OK
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Abington Memorial Hospital
mi
from
Abington, PA
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Abington Memorial Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Women and Infants Hospital
mi
from
Providence, RI
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Women and Infants Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
AnMedical Health Cancer Center
mi
from
Anderson, SC
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
AnMedical Health Cancer Center
mi
from
Anderson, SC
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Carilion Clinic Gynecological Oncology
mi
from
Roanoke, VA
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Carilion Clinic Gynecological Oncology
mi
from
Roanoke, VA
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
Lakeland Hospital
mi
from
Saint Joseph, MI
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
Lakeland Hospital
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated:  12/1/2017
MedStar Washington Hospital Center
mi
from
Washington,
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
A Phase II Evaluation of Combination Bevacizumab (NCI-Supplied Agent: NSC #70486) and Temsirolimus (CCI-779, NCI-Supplied Agent, NSC #683864) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Status: Enrolling
Updated: 12/1/2017
MedStar Washington Hospital Center
mi
from
Washington,
Click here to add this to my saved trials
Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer
A Phase II Trial of Induction Carboplatin and Docetaxel Followed by Radiotherapy Then Consolidation Chemotherapy With Carboplatin and Docetaxel in Stage III, IV and Recurrent Endometrial Cancer
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer
A Phase II Trial of Induction Carboplatin and Docetaxel Followed by Radiotherapy Then Consolidation Chemotherapy With Carboplatin and Docetaxel in Stage III, IV and Recurrent Endometrial Cancer
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer
A Phase II Trial of Induction Carboplatin and Docetaxel Followed by Radiotherapy Then Consolidation Chemotherapy With Carboplatin and Docetaxel in Stage III, IV and Recurrent Endometrial Cancer
Status: Enrolling
Updated:  12/3/2017
Park Nicollet Cancer Center
mi
from
Saint Louis Park, MN
Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer
A Phase II Trial of Induction Carboplatin and Docetaxel Followed by Radiotherapy Then Consolidation Chemotherapy With Carboplatin and Docetaxel in Stage III, IV and Recurrent Endometrial Cancer
Status: Enrolling
Updated: 12/3/2017
Park Nicollet Cancer Center
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers
Phase II Study of 852A Administered Subcutaneously in Patients With Metastatic Refractory Breast, Ovarian, Endometrial and Cervical Cancers
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers
Phase II Study of 852A Administered Subcutaneously in Patients With Metastatic Refractory Breast, Ovarian, Endometrial and Cervical Cancers
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial
Status: Enrolling
Updated:  12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial
Status: Enrolling
Updated: 12/3/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial
Status: Enrolling
Updated:  12/3/2017
Crozer-Chester Medical Center
mi
from
Upland, PA
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
Women's Cancer Center Protocol #45: Prolonged Venous Thromboembolism Prophylaxis With Fondaparinux in Gynecologic Oncology Patients: An Open Label Phase II Trial
Status: Enrolling
Updated: 12/3/2017
Crozer-Chester Medical Center
mi
from
Upland, PA
Click here to add this to my saved trials
CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer
WCC# 44: A Pilot Study of CerviPrep, a Novel Drug Delivery Device for the Cervix, in the Local Administration of Gemcitabine, a Radiation Sensitizer
Status: Enrolling
Updated:  12/3/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer
WCC# 44: A Pilot Study of CerviPrep, a Novel Drug Delivery Device for the Cervix, in the Local Administration of Gemcitabine, a Radiation Sensitizer
Status: Enrolling
Updated: 12/3/2017
University of Minnesota Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Cervical Cancer Screening Project Part C
Minnesota Community Networks Center for Eliminating Cancer Disparities: Cervical Cancer Screening Project Part C Quantitative
Status: Enrolling
Updated:  12/8/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Cervical Cancer Screening Project Part C
Minnesota Community Networks Center for Eliminating Cancer Disparities: Cervical Cancer Screening Project Part C Quantitative
Status: Enrolling
Updated: 12/8/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Mind-body Intervention to Improve Body and/or Self Image
A Mind-body Intervention to Improve Body and/or Self Image: a Phase II Randomized Trial
Status: Enrolling
Updated:  12/10/2017
University of Michigan, School of Nursing
mi
from
Ann Arbor, MI
A Mind-body Intervention to Improve Body and/or Self Image
A Mind-body Intervention to Improve Body and/or Self Image: a Phase II Randomized Trial
Status: Enrolling
Updated: 12/10/2017
University of Michigan, School of Nursing
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/12/2017
Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
mi
from
Orange, CA
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/12/2017
Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/12/2017
University of Mississippi Cancer Clinic
mi
from
Jackson, MS
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/12/2017
University of Mississippi Cancer Clinic
mi
from
Jackson, MS
Click here to add this to my saved trials
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/12/2017
MetroHealth Cancer Care Center at MetroHealth Medical Center
mi
from
Cleveland, OH
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/12/2017
MetroHealth Cancer Care Center at MetroHealth Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/12/2017
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/12/2017
Oklahoma University Cancer Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/12/2017
Cancer Care Associates - Saint Francis Campus
mi
from
Tulsa, OK
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/12/2017
Cancer Care Associates - Saint Francis Campus
mi
from
Tulsa, OK
Click here to add this to my saved trials
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/12/2017
Parkland Memorial Hospital
mi
from
Dallas, TX
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/12/2017
Parkland Memorial Hospital
mi
from
Dallas, TX
Click here to add this to my saved trials
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/12/2017
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/12/2017
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/12/2017
Lyndon B. Johnson General Hospital
mi
from
Houston, TX
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/12/2017
Lyndon B. Johnson General Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/12/2017
Carilion Gynecologic Oncology Associates
mi
from
Roanoke, VA
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/12/2017
Carilion Gynecologic Oncology Associates
mi
from
Roanoke, VA
Click here to add this to my saved trials
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/12/2017
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/12/2017
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/12/2017
Women's Cancer Center - La Canada
mi
from
Las Vegas, NV
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/12/2017
Women's Cancer Center - La Canada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated:  12/12/2017
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix
Status: Enrolling
Updated: 12/12/2017
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
A Phase II Trial of Bevacizumab (rhuMAB VEGF) (NSC #704865) in the Treatment of Persistent and Recurrent Squamous Cell Carcinoma of the Cervix (Group A)
Status: Enrolling
Updated:  12/27/2017
Gynecologic Oncology Group
mi
from
Philadelphia, PA
Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix
A Phase II Trial of Bevacizumab (rhuMAB VEGF) (NSC #704865) in the Treatment of Persistent and Recurrent Squamous Cell Carcinoma of the Cervix (Group A)
Status: Enrolling
Updated: 12/27/2017
Gynecologic Oncology Group
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Racial Disparity in Endometrial Cancer
Racial Disparity in Prevalence and Survival Rates in Endometrial Cancer
Status: Enrolling
Updated:  1/5/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Racial Disparity in Endometrial Cancer
Racial Disparity in Prevalence and Survival Rates in Endometrial Cancer
Status: Enrolling
Updated: 1/5/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Home-Based or Clinic-Based Human Papillomavirus (HPV) Screening
Cytology vs. at Home HPV Screening for Detection of CIN 2,3,CIS
Status: Enrolling
Updated:  1/8/2018
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Home-Based or Clinic-Based Human Papillomavirus (HPV) Screening
Cytology vs. at Home HPV Screening for Detection of CIN 2,3,CIS
Status: Enrolling
Updated: 1/8/2018
University of Minnesota, Masonic Cancer Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Home-Based or Clinic-Based Human Papillomavirus (HPV) Screening
Cytology vs. at Home HPV Screening for Detection of CIN 2,3,CIS
Status: Enrolling
Updated:  1/8/2018
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Home-Based or Clinic-Based Human Papillomavirus (HPV) Screening
Cytology vs. at Home HPV Screening for Detection of CIN 2,3,CIS
Status: Enrolling
Updated: 1/8/2018
Fred Hutch/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated:  1/9/2018
University of South Alabama Mitchell Cancer Institute
mi
from
Mobile, AL
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated: 1/9/2018
University of South Alabama Mitchell Cancer Institute
mi
from
Mobile, AL
Click here to add this to my saved trials
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated:  1/9/2018
Saint Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary
Status: Enrolling
Updated: 1/9/2018
Saint Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials